KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Thermo Fisher Scientific (TMO) Interest Expenses (2019 - 2025)

Thermo Fisher Scientific's Interest Expenses history spans 14 years, with the latest figure at $365.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Interest Expenses rose 15.14% year-over-year to $365.0 million, compared with a TTM value of $1.4 billion through Dec 2025, up 2.09%, and an annual FY2025 reading of $1.4 billion, up 2.09% over the prior year.
  • Interest Expenses for Q4 2025 was $365.0 million at Thermo Fisher Scientific, up from $347.0 million in the prior quarter.
  • The five-year high for Interest Expenses was $404.0 million in Q2 2025, with the low at $122.0 million in Q3 2021.
  • Average Interest Expenses over 5 years is $272.3 million, with a median of $310.0 million recorded in 2024.
  • Year-over-year, Interest Expenses soared 120.59% in 2023 and then dropped 18.72% in 2024.
  • Tracing TMO's Interest Expenses over 5 years: stood at $161.0 million in 2021, then surged by 67.08% to $269.0 million in 2022, then soared by 44.98% to $390.0 million in 2023, then dropped by 18.72% to $317.0 million in 2024, then rose by 15.14% to $365.0 million in 2025.
  • Per Business Quant, the three most recent readings for TMO's Interest Expenses are $365.0 million (Q4 2025), $347.0 million (Q3 2025), and $404.0 million (Q2 2025).